Is aTyr Pharma, Inc. (ATYR) a Buy, Sell, or Hold?
aTyr Pharma, Inc.
NASDAQ:ATYR
$0.486 USD
-$0.02 (-3.59%)
- Volume
- 0
- Average Volume
- 2.66M
- Market Capitalization
- $47.65M
- P/E Ratio
- -0.67
- Dividend Yield
- 0.00%
- Price Target
- $1.25
- Year High
- $7.29
- Year Low
- $0.40
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.78
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Sanjay S. Shukla |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ATYR |
| CUSIP | 002120202 |
| CIK | 0001339970 |
| Web | https://www.atyrpharma.com |
| Phone | 858 731 8389 |
| Currency | USD |
| Employees | 58 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.20 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.78 |
| Quick Ratio | 5.78 |
| Cash Ratio | 0.86 |
Sales & Book Value
| Annual Sales | $190K |
| Price / Sales | 250.80 |
| Cash Flow | -0.60 |
| Price / Cash Flow | -0.80 |
| Price / Book | 0.82 |
Price Target and Rating
| Average Stock Price Forecast | $1.25 |
| High Stock Price Forecast | $17.00 |
| Low Stock Price Forecast | $1.00 |
| Forecast Upside/Downside | -61.12% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.8 |
| Trailing P/E Ratio | -0.67 |
| PEG Ratio | -0.07 |
| P/E Growth | -0.07 |
| Net Income | $-74.12M |
| Net Margin | -36857.37% |
| Pretax Margin | -36859.47% |
| Return on Equity | -99.87% |
| Return on Assets | -87.92% |
Financials Score
| AltmanZ Score | -11.48 |
| Piotroski Score | 2.00 |
| Working Capital | 55.88M |
| Total Assets | 79.65M |
| Ebit | -70.03M |
| Market Cap | 52.06M |
| Total Liabilities | 21.91M |
Poll Results
About aTyr Pharma, Inc. (NASDAQ:ATYR) Stock
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline fea ... tures ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
2026-05-15 08:00:00
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint.
aTyr Pharma to Participate in Upcoming Investor Conferences
2026-05-13 16:01:00
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in May and June 2026. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 20, 2026Location: New York, NYFormat: 1x1 Investor Meetings Conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Time: 3:45pm ETLocation: New York, NYFormat: Fireside ChatSpeaker: Sanjay S.
2026-05-12 09:21:02
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
2026-05-11 20:09:19
aTyr Pharma NASDAQ: ATYR said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting.
2026-05-11 16:01:00
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint.
Frequently Asked Questions
-
What is the current aTyr Pharma, Inc. (ATYR) stock price?
-
aTyr Pharma, Inc.(NASDAQ:ATYR) stock price is $0.486 in the last trading session. During the trading session, ATYR stock reached the peak price of $7.29 while $0.395 was the lowest point it dropped to. The percentage change in ATYR stock occurred in the recent session was --3.59% while the dollar amount for the price change in ATYR stock was -$-0.02.
-
ATYR's industry and sector of operation?
-
The NASDAQ listed ATYR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ATYR?
-
Peter Villiger | Vice President of Corporate Development
Leslie Nangle | Vice President of Research
Jill Broadfoot | Chief Financial Officer
Ashlee Dunston | Director of Investor Relations & Corporate Communications
Dalia R. Rayes | Head of Commercial, Global Efzofitimod Franchise -
How many employees does ATYR have?
-
Number of ATYR employees currently stands at 58. ATYR operates from 10240 Sorrento Valley Road, San Diego, CA 92121, US.
-
Link for ATYR official website?
-
Official Website of ATYR is: https://www.atyrpharma.com
-
How do I contact ATYR?
-
ATYR could be contacted at phone #858 731 8389 and can also be accessed through its website. ATYR operates from 10240 Sorrento Valley Road, San Diego, CA 92121, US.
-
How many shares of ATYR are traded daily?
-
The average number of ATYR shares traded daily for last 3 months was 2.66M.
-
What is the market cap of ATYR currently?
-
The market value of ATYR currently stands at $47.65M with its latest stock price at $0.486